Background Evidence for limiting the extent of surgery in patients with low‐risk thyroid cancer is lacking. Methods A systematic search was performed according to the PRISMA and MOOSE guidelines to assess the effect of total thyroidectomy (TT) with or without radioactive iodine (RAI) treatment versus hemithyroidectomy (HT) on recurrence and overall mortality in patients with differentiated (papillary or follicular) T1–2 N0 thyroid cancer. PubMed, Embase and Cochrane databases were searched, and two authors independently assessed the articles. Results A total of ten eligible articles were identified. All were observational cohort series, representing a total of 23 134 patients, of which 17 699 were available for meta‐analysis. Six studies included patients who had TT followed by RAI treatment. The pooled recurrence rate after TT ± RAI and HT was 2·3 and 2·8 per cent respectively (odds ratio (OR) 1·12, 95 per cent c.i. 0·82 to 1·53; P = 0·48). The pooled 20‐year overall survival rate after TT ± RAI was 96·8 per cent, compared with 97·4 per cent for HT (OR 1·30, 0·71 to 2·37; P = 0·40). Overall, higher complication rates were found in the TT ± RAI group. Conclusion Recurrence rates after HT for treatment of well differentiated T1–2 N0 thyroid cancer were similar to those after TT ± RAI, with a lower incidence of treatment‐related complications.
2 June 2023 in JNCI: Journal of the National Cancer Institute
Background: The impact of multifocality and bilaterality on recurrence in patients with low-risk papillary thyroid cancer (PTC) is relevant when considering patients for a de-escalated treatment strategy: hemithyroidectomy instead of total thyroidectomy followed with or without radioactive iodine. This study aims to analyze contralateral tumor probability in patients treated for low-risk PTC and assess multifocality and bilaterality as possible predictors for recurrence. Methods: Patients with low-risk PTC treated with total thyroidectomy followed with or without radioactive iodine in the Netherlands between 2005 and 2015 were included in this study. Patients were identified from the Netherlands Comprehensive Cancer Organization (IKNL) and linked with the nationwide network and registry of Pathology in the Netherlands (PALGA). Contralateral tumor probability and recurrence were assessed. Results: Of 791 included patients, 41.8% (331 of 791) had multifocal disease, with 68.9% (228 of 331) of those patients having bilateral disease. The contralateral tumor probability after hemithyroidectomy was 24.6% (150 of 610) for patients with unifocal disease and 43.1% (78 of 181) for patients with multifocal disease. We found a higher trend of recurrence in patients with bilateral disease, regardless of multifocality: in patients with contralateral disease after precompletion diagnosed unifocal disease 7.3% (11 of 150) had recurrent disease, and patients without contralateral disease after precompletion diagnosed multifocal disease 1.9% (2 per 103) had recurrence. Cox regression analysis showed that bilaterality (hazard ratio = 3.621, 95% confidence interval = 1.548 to 8.471) was the sole statistically significant risk factor for recurrence. Conclusion: Low recurrence rates are found in patients with either multifocal or bilateral disease with low-risk PTC. Bilaterality should be taken into account when considering these patients for de-escalated treatment strategy.
1 January 2018 in Therapeutic Advances in Medical Oncology
Introduction: Stereotactic body (or ablative) radiotherapy (SBRT/SABR) is now a guideline-recommended treatment for medically inoperable patients with peripherally-located, stage I non-small cell lung cancer (NSCLC), and for medically operable patients who decline surgery. The 5-year local failure rate after SBRT is about 10% and in highly selected patients, surgery has been used as a salvage therapy. We performed a systematic review to address the feasibility, safety, and outcome of salvage surgery for locally recurrent early stage NSCLC after SBRT. Methods: A systematic literature search was performed according to Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. PubMed, Embase and Cochrane databases were searched and two authors independently assessed the articles. A total of seven eligible articles were identified. Results: All seven articles were retrospective case series, representing a total of 47 patients. Surgery was completed in all patients. Where reported in sufficient detail, morbidity (four studies) was between 29 and 50% (series of two patients) and 90-day mortality (six studies) was between 0% (four studies) and 11% ( n = 1, disease progression). Median ( n = 5)/mean ( n = 1) reported or calculated follow ups were 7–54.5/17.3 months. Median overall survival was reported in three studies and ranged between 13.6–82.7 months. Crude survival in three others was 2–35 months. Conclusion: Limited, low-level evidence prevents firm conclusions, but based on the existing data, salvage surgery after local recurrence of NSCLC following SBRT appears technically feasible, with acceptable morbidity and mortality in appropriately selected and counselled patients who are fit enough and who accept the risks (level of evidence 4, strength of recommendation C).
Introduction: The 2015 American Thyroid Association guidelines recommend de‐escalating surgical treatment for papillary thyroid cancer (PTC). We hypothesize that the Dutch PTC population might differ due to a restrictive diagnostic policy that mainly selects symptomatic and palpable thyroid nodules for further diagnostics, potentially selecting relatively more aggressive tumors. We aimed to describe the Dutch PTC population because differences in populations can have consequences for the adoption of foreign guidelines.Methods: From the Dutch national cancer registry, patients diagnosed with pT1–T3 PTC between 2005 and 2015 were included. Baseline characteristics, disease‐free interval, and overall survival were compared between low‐risk and non‐low risk PTC. Furthermore, the TNM stage of the Dutch and U.S. cohorts were compared via literature search.Results: Of the 3368 pT1‐T3 patients included, 1813 (53.8%) had a low‐risk PTC, and 1555 (46.2%) had a non‐low‐risk PTC. In the Dutch PTC population, pT1 tumors occurred in 45.8%, pT2 and pT3 tumors occurred in 34.9% and 19.3% of the patients, respectively. Of all patients, 10.2% had central lymph node metastases and 16.6% had lateral lymph node metastasis. Distant metastasis only occurred in 18 (0.5%) of the patients. The 10‐year overall survival was 89.6%, with rates of 91.6% for low‐risk and 87.3% for non‐low‐risk patients (p = < 0.001). During the follow‐up period, 257 patients (7.6%) had a recurrence.Discussion: The higher frequency of advanced tumors among the Dutch PTC population in contrast to the U.S. emphasizes the need for careful national data analyses before the adoption of surgical intervention de‐escalation protocols from other countries.
Background: Hypoparathyroidism is a complication associated with significant morbidity and results from inadvertent removal of the parathyroid during thyroid surgery. Therefore, intra‐operative identification of parathyroid tissue is essential to minimize the risk of hypoparathyroidism. Current identification techniques come with significant limitations in logistics and accuracy. We therefore propose higher‐harmonic generation microscopy (HHGM), a rapid, non‐invasive, label‐free method for the real‐time visualization of human tissue, as a potential alternative.Methods: A prospective proof‐of‐concept study was conducted at the Amsterdam University Medical Centers from February to April 2024. Intra‐operative HHGM imaging of presumed parathyroid tissue samples was performed, and the results were compared with conventional histopathology by an expert endocrine pathologist in order to evaluate the sensitivity and specificity of HHGM. The logistical process and its potentially associated benefits were also evaluated.Results: Intraoperative imaging was performed on 32 fresh, unprocessed tissue samples from 18 patients. HHGM demonstrated a high sensitivity (85%) and specificity (83.3%) for the detection of parathyroid tissue. HHGM imaging was found to be more time‐efficient than frozen section, taking ~5 min per biopsy compared to 30 min for FS. HHGM was able to produce high‐quality images in cases where frozen section analysis was inconclusive due to insufficient tissue. Logistical challenges and extra workload associated with HHGM were minimal.Conclusion: This proof‐of‐concept study demonstrates that HHGM could be a promising intraoperative diagnostic imaging modality, offering rapid imaging and detailed visualization capabilities. These features suggest that HHGM might potentially reduce surgery duration and decrease demand on pathology resources.